225 related articles for article (PubMed ID: 10776972)
1. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
[TBL] [Abstract][Full Text] [Related]
3. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
5. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
[TBL] [Abstract][Full Text] [Related]
6. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
11. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
14. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
[TBL] [Abstract][Full Text] [Related]
20. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
